Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities

被引：2
|
作者：
Dimopoulos, Meletios A. [1 ]
Kastritis, Efstathios [1 ]
Christoulas, Dimitrios [1 ]
Migkou, Magdalini [1 ]
Gavriatopoulou, Maria [1 ]
Gkotzamanidou, Maria [1 ]
Iakovaki, Marina [1 ]
Roussou, Maria [1 ]
Efstathiou, Eleni [1 ]
Terpos, Evangelos [1 ]
机构：
[1] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.958.958
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：395 / 396
页数：2
相关论文
共 50 条
  • [1] Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    Dimopoulos, M. A.
    Kastritis, E.
    Christoulas, D.
    Migkou, M.
    Gavriatopoulou, M.
    Gkotzamanidou, M.
    Iakovaki, M.
    Matsouka, C.
    Mparmparoussi, D.
    Roussou, M.
    Efstathiou, E.
    Terpos, E.
    LEUKEMIA, 2010, 24 (10) : 1769 - 1778
  • [2] Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    M A Dimopoulos
    E Kastritis
    D Christoulas
    M Migkou
    M Gavriatopoulou
    M Gkotzamanidou
    M Iakovaki
    C Matsouka
    D Mparmparoussi
    M Roussou
    E Efstathiou
    E Terpos
    Leukemia, 2010, 24 : 1769 - 1778
  • [3] Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Zagouri, Flora
    Terpos, Evangelos
    BLOOD, 2008, 112 (11) : 608 - 608
  • [4] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [5] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [6] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Takashi Yoshida
    Masaki Ri
    Haruna Fujinami
    Yoshiko Oshima
    Takuto Tachita
    Yoshiaki Marumo
    Hirokazu Sasaki
    Shiori Kinoshita
    Haruhito Totani
    Tomoko Narita
    Ayako Masaki
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2019, 110 : 228 - 236
  • [7] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Yoshida, Takashi
    Ri, Masaki
    Fujinami, Haruna
    Oshima, Yoshiko
    Tachita, Takuto
    Marumo, Yoshiaki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Totani, Haruhito
    Narita, Tomoko
    Masaki, Ayako
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (02) : 228 - 236
  • [8] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [9] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [10] CYTOGENETIC IMPACT ON LENALIDOMIDE TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EVALUATION
    Zambello, R.
    Berno, T.
    Bonaldi, L.
    Sechettin, E.
    De March, E.
    Branca, A.
    Albana, L.
    Minotto, C.
    Briani, C.
    Gurrieri, C.
    Temporin, F.
    Sammartin, K.
    Piazza, F.
    Cavraro, M.
    Trentin, L.
    Semenzato, G.
    HAEMATOLOGICA, 2014, 99 : 643 - 643
12345